2025-09-11 - Analysis Report
Okay, here's an analysis of Merck & Co. Inc. (MRK) based on the provided data, presented in English with numerical highlights and concise summaries.

## Merck & Co. Inc. (MRK) Analysis

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops and markets a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -7.75%
*   **VOO Cumulative Return:** 39.61%
*   **Divergence:**
    *   Current Divergence: -108.9
    *   Relative Divergence: 2.2 (Indicates MRK is near the lower end of its historical divergence range compared to VOO)

**Analysis:** MRK has significantly underperformed the S&P 500 over the period. The Relative Divergence suggests that this underperformance is near the extreme of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD   | Alpha    | Beta   | Cap(B) |
| :----------- | :-------- | :---- | :------- | :----- | :----- |
| 2015-2017  | 5.0%      | 58.2% | 5.0%     | 1.0    | 133.2  |
| 2016-2018  | 43.0%     | 66.4% | 43.0%    | 1.0    | 180.9  |
| 2017-2019  | 40.0%     | 66.4% | 40.0%    | 1.0    | 215.3  |
| 2018-2020  | 20.0%     | 66.4% | 20.0%    | 1.0    | 193.6  |
| 2019-2021  | -1.0%     | 65.6% | -2.0%    | 0.0    | 190.1  |
| 2020-2022  | 13.0%     | 69.5% | 24.0%    | -0.0   | 275.2  |
| 2021-2023  | 31.0%     | 69.5% | 22.0%    | -0.0   | 270.4  |
| 2022-2024  | -7.0%     | 69.5% | -37.0%   | -0.0   | 246.8  |
| 2023-2025  | -60.0%    | 71.5% | -105.0%  | 0.0    | 209.9  |

**Analysis:**

*   **Alpha:** MRK's alpha shows a decline in recent periods, indicating decreasing outperformance (or increasing underperformance) relative to its benchmark.  The recent negative alpha values suggest significant underperformance.
*   **Beta:** Beta values close to 0 in recent years suggest MRK's price movements have become less correlated with the overall market.
*   **CAGR:** The Compound Annual Growth Rate (CAGR) has deteriorated significantly in the most recent period.
*   **MDD:** The Maximum Drawdown (MDD) remains high, indicating substantial potential losses from peak to trough.
*   **Cap:** Market Capitalization has fluctuated, reflecting market sentiment and company performance.

### 2. Recent Stock Price Movement

*   **Current Price:** 84.03
*   **Previous Close:** 84.61
*   **Change:** -0.69 (Slight decrease)
*   **5-Day Moving Average:** 84.33
*   **20-Day Moving Average:** 84.26
*   **60-Day Moving Average:** 82.17

**Analysis:**  The stock price has experienced a slight decrease in the most recent trading session. The 5-day and 20-day moving averages are very close, suggesting a period of consolidation. The 60-day moving average is lower, indicating that the recent price is above the longer-term trend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 48.54 (Neutral)
*   **PPO:** -0.15 (Slightly Bearish)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Recent Relative Divergence Change:** 2.2 (Positive, indicating short-term improvement in relative performance)
*   **Expected Return:** -596.4% (Significant negative projected return relative to the S&P 500 over a long-term investment horizon)

**Analysis:** The MRI indicates a low-risk environment, while the RSI is neutral. The PPO is slightly negative. The Hybrid Signal recommends buying with caution, indicating some potential upside but also acknowledges risk.  The positive change in relative divergence offers a glimmer of short-term improvement. The Expected Return is extremely negative, suggesting significant concerns about future performance relative to the market. The recent price change of -0.69, combined with the high Expected Return, highlights potential instability and should be considered carefully.

### 4. Recent News & Significant Events

*   **[2025-09-10] Sector Update: Health Care Stocks Retreat Late Afternoon**
*   **[2025-09-10] US pharma giant Merck ditches plan for $1.4-bn research centre in UK**
*   **[2025-09-10] Sector Update: Health Care Stocks Lower in Afternoon Trading**
*   **[2025-09-10] Sector Update: Health Care**
*   **[2025-09-10] Market Chatter: Merck Abandons London Research Center, Citing 'Uncompetitive' UK**
*   **[2025-09-10] Merck to scrap London drug research centre**

**Analysis:** The news is largely negative, focusing on the cancellation of a significant research center in the UK. This could negatively impact investor sentiment and future growth expectations. The general updates on the health care sector's retreat also add to a cautious outlook.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (~Buy)
*   **Opinions:** 24
*   **Target Price (avg/high/low):** 102.33 / 141.00 / 82.00
*   **Recent Rating Changes:** No significant changes reported.

**Analysis:** Despite the recent negative news and underperformance, analysts maintain a "Buy" consensus with a target price significantly above the current price.  However, it's important to consider the recency and weighting of these analyst opinions, especially in light of the recent news. The $82 low price target is near the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue      |
| :---------- | :--- | :----------- |
| 2025-08-05 | 1.76 | $15.81B      |
| 2025-05-02 | 2.01 | $15.53B      |
| 2024-11-06 | 1.25 | $16.66B      |
| 2024-08-05 | 2.15 | $16.11B      |
| 2025-08-05 | 2.15 | $16.11B      |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated over the past few quarters. There appears to be some inconsistency in the data (duplicate date). Revenue shows a slight downward trend from late 2024 to mid-2025.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
| :--------- | :-------- | :------ |
| 2025-06-30 | $48.99B   | 9.04%   |
| 2025-03-31 | $48.34B   | 10.51%  |
| 2024-12-31 | $46.31B   | 8.08%   |
| 2024-09-30 | $44.50B   | 7.09%   |
| 2024-06-30 | $43.58B   | 12.52%  |

**Analysis:** Revenue has generally been stable, with a slight decrease in the most recent quarter. Profit margins are strong, consistently above 75%. Equity has been increasing, but Return on Equity (ROE) has fluctuated, showing a decline in the most recent period.

### 7. Overall Analysis

MRK is currently facing several challenges. The stock has significantly underperformed the S&P 500, and recent news regarding the cancellation of a research center has likely dampened investor sentiment. While analysts maintain a "Buy" rating, the negative Expected Return and recent earnings trends warrant caution.

**Key Considerations:**

*   **Underperformance:** The significant underperformance relative to the S&P 500 is a major concern.
*   **News Impact:** The cancellation of the research center could have long-term implications for innovation and growth.
*   **Conflicting Signals:** Analyst ratings are positive, but technical indicators and the Expected Return suggest caution.
*   **Financial Health:** While revenue and profit margins remain strong, ROE has been declining.

**Recommendation:**

Given the conflicting signals and negative news, a cautious approach is warranted. It would be prudent to closely monitor the company's performance in the coming quarters and reassess the investment thesis based on new data.
